Mediwhale Raises $13.3M for Retinal AI Cardiovascular Software

South Korean medical AI innovator, Mediwhale, has successfully closed a Series C funding round, securing $13.3 million. This significant capital infusion, led by Premier Partners with participation from KB Investment, Quad Investment Management, IMM Investment, Hana Ventures, AON Investment, and Startup Partners, propels the company's total funding to over $34 million. The investment underscores growing confidence in AI's potential to revolutionize diagnostic capabilities within the healthcare sector, particularly in early disease detection.

Mediwhale specializes in developing sophisticated artificial intelligence algorithms that analyze retinal images to predict the risk of cardiovascular and cardiometabolic diseases, including chronic kidney disease. Their flagship product, Dr. Noon CVD, stands as a pioneering solution globally, offering a non-invasive, radiation-free method for assessing cardiovascular health. This technology achieves diagnostic accuracy comparable to traditional cardiac CT scans, delivering results in mere minutes. The system is already implemented in over 170 medical facilities both domestically and internationally, demonstrating strong market adoption.

The newly acquired funds are earmarked for aggressive global expansion, with a strategic focus on the United States market. Mediwhale plans to advance clinical trials and pursue crucial regulatory approvals, including FDA De Novo clearance. The company also aims to bolster its commercialization infrastructure and broaden its product portfolio to address other metabolic conditions. Establishing proof-of-concept installations within U.S. primary care settings is a key objective to build early commercial traction and validate the technology's real-world impact.

This funding round arrives as Mediwhale also prepares for a public offering. The company is actively pursuing a listing on the KOSDAQ exchange within the first half of next year, utilizing a special technology listing pathway. This dual strategy of private funding and public market preparation signals a mature growth phase and ambition for significant scale.

The investment from a consortium of prominent venture capital firms highlights the compelling market opportunity in AI-driven diagnostics. The global AI in healthcare market is projected to experience substantial growth, driven by the demand for more efficient, accurate, and accessible diagnostic tools. Mediwhale's approach, leveraging the eye as a window to systemic health, addresses a critical unmet need in preventative cardiovascular care, a leading cause of mortality worldwide. The company's proprietary technology and established commercial footprint were cited as key drivers for the investment.

Taegeun Choi, CEO of Mediwhale, expressed his enthusiasm, stating, "This round is a strong validation of Mediwhale’s technology and commercial value from the capital markets. We’ll build on this momentum to secure FDA De Novo clearance and take our next step as a global healthcare company." The successful Series C financing positions Mediwhale to further solidify its market leadership and accelerate its mission to transform cardiovascular risk assessment through advanced AI.